Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Status Completed

Clinical Trial Summary

This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA). Investigational product will be applied topically once daily for 52 weeks. Cohort 1 will be rollover participants from study ARQ-154-203 (NCT04091646) and will roll into treatment in the current study without interruption. Cohort 2 will include participants from ARQ-154-203 who began treatment in the current study after a gap from completing treatment in the prior study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04445987
Study type	Interventional
Source	Arcutis Biotherapeutics, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	June 12, 2020
Completion date	November 19, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01703793` - Safety and Efficacy Study in Subjects With Seborrheic Dermatitis	Phase 2
Completed	`NCT01203189` - Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo	N/A
Completed	`NCT00991198` - The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage	Phase 2
Completed	`NCT03567980` - A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis	Phase 4
Recruiting	`NCT03688971` - Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis	Phase 2
Recruiting	`NCT01139749` - Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea	Phase 4
Completed	`NCT05105139` - Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
Completed	`NCT01591070` - Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis	Phase 4
Completed	`NCT05787860` - Ruxolitinib in Seborrheic Dermatitis	Phase 2
Completed	`NCT00403559` - A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis	Phase 2
Not yet recruiting	`NCT00767546` - Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients	Phase 1
Recruiting	`NCT01315951` - Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation	N/A
Recruiting	`NCT05942248` - The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis	N/A
Recruiting	`NCT06013371` - PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea	Phase 2
Recruiting	`NCT05319444` - Cleansing Device for the Treatment of Scalp and Hair Conditions	N/A
Completed	`NCT04973228` - Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)	Phase 3
Completed	`NCT03114111` - Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis	Early Phase 1
Completed	`NCT02656368` - Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis	N/A
Completed	`NCT00830908` - HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis	N/A
Completed	`NCT02349854` - Neurobiology of the Scalp in Seborrheic Dermatitis	N/A